A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells.

Published on Jan 1, 2021in Clinical And Translational Immunology6.464
· DOI :10.1002/CTI2.1291
Objectives null Chimeric antigen receptor (CAR)-T cell therapy possesses the potential to cause unexpected on-target toxicities that may be life-threatening. Non-human primates (NHPs) share considerable structural homology and expression profiles of most proteins with humans and are therefore utilised as an animal model for non-clinical safety studies. We have developed a lymphodepleted NHP model by conditioning the animals with immunosuppressive chemotherapy designed to simulate clinical practice conditions, to induce transient mixed chimerism before the administration of human CAR-T cells redirected to target Ephrin type-B receptor 4 (EPHB4-CAR-T cells) to evaluate the toxicity of these cells. null Methods null We administered 60 mg m-2 day-1 of fludarabine for 4 days and 30 mg kg-1 day-1 of cyclophosphamide for 2 days intravenously to cynomolgus macaques for lymphodepletion; then, 3.3 × 106 kg-1 of non-transduced or EPHB4-CAR-T cells was infused into the macaques, respectively. All macaques were closely monitored and evaluated for potential toxicity for 7 days. null Results null Lymphodepletion was successfully achieved on day -1 before T-cell infusion and persisted over 7 days without severe organ toxicities. A single administration of human EPHB4-CAR-T cells did not induce overt organ toxicities, although EPHB4-CAR-T cells were activated in vivo as evidenced by the elevation in copy numbers of the CAR transgene 24 h after infusion. null Conclusion null Although this NHP model is limited for the full evaluation of toxicity of human CAR-T cells and the conditioning protocol should be further optimised, this lymphodepleted NHP model could be used to assess acute on-target/off-tumor toxicities of CAR-T cells.
#1Kayoko Nakamura (Shinshu University)
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 9 authors...
Abstract The quality of chimeric antigen receptor (CAR)-T cell products, including the expression of memory and exhaustion markers, has been shown to influence their long-term functionality. The manufacturing process of CAR-T cells should be optimized to prevent early T cell exhaustion during expansion. Activation of T cells by monoclonal antibodies is a critical step for T cell expansion, which may sometimes induce excess stimulation and exhaustion of T cell. Given that piggyBac transposon (PB)...
1 CitationsSource
#1Hiroshi Kubo (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 14
Last. Hajime Hosoi (Kyoto Prefectural University of Medicine)H-Index: 33
view all 9 authors...
Abstract Ephrin type-B receptor 4 (EPHB4), expressed in tumors including rhabdomyosarcoma, is a suitable target for chimeric antigen receptor (CAR)-T cells. Ligand independent activation of EPHB4 causes cell proliferation and malignant transformation in rhabdomyosarcoma, whereas ligand-dependent stimulation of EPHB4 induces apoptosis in rhabdomyosarcoma. Therefore, we hypothesized that ligand-based EPHB4-specific CAR-T cells may kill rhabdomyosarcoma cells without stimulating downstream cell pro...
2 CitationsSource
#1Juan Fu (Johns Hopkins University)H-Index: 11
#2Young J. Kim (VUMC: Vanderbilt University Medical Center)H-Index: 31
With the rapid approval of immune checkpoint inhibitors for lung, melanoma, breast, genitourinary, and hematological malignancies, the hematopoietic cells in the tumor microenvironment (TME) are now considered an important, if not essential, consideration for cancer scientists. In many instances, syngeneic murine models have not been highly predictive for responsiveness in clinical trials. Our limited understanding of the human TME have, therefore, precluded a rational translation of immunothera...
1 CitationsSource
#1Hirokazu Morokawa (Shinshu University)H-Index: 2
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 9 authors...
Objectives Chimeric antigen receptor (CAR)-T cell therapy redirected to specific antigens on tumor cells is a promising immunotherapy strategy for various cancers. Most target antigens are also expressed on normal tissues at varying levels, and therefore, a considerable challenge in the field is determining safety profiles, including life-threatening off-tumor and off-target toxicities. The granulocyte-macrophage colony-stimulating factor receptor (hGMR) is a promising target for CAR T-cell ther...
2 CitationsSource
#1Yoshie Kametani (Tokai University)H-Index: 13
#2Yusuke Ohno (Tokai University)H-Index: 1
Last. Yutaka Tokuda (Tokai University)H-Index: 32
view all 8 authors...
Peptide vaccination was developed for the prevention and therapy of acute and chronic infectious diseases and cancer. However, vaccine development is challenging, because the patient immune system requires the appropriate human leukocyte antigen (HLA) recognition with the peptide. Moreover, antigens sometimes induce a low response, even if the peptide is presented by antigen-presenting cells and T cells recognize it. This is because the patient immunity is dampened or restricted by environmental...
12 CitationsSource
#1Yeongbeen Kwon (SKKU: Sungkyunkwan University)H-Index: 1
#2Kyo Won Lee (SMC: Samsung Medical Center)H-Index: 14
Last. Sung Joo Kim (SKKU: Sungkyunkwan University)H-Index: 30
view all 9 authors...
Bone marrow preconditioning using cyclophosphamide (CP) is generally used for bone marrow transplantation (BMT). However, because of CP's hepatotoxicity and nephrotoxicity, additional fludarabine (FDR) administration and a reduced dose of CP are used for reduced-intensity preconditioning. Recently, preclinical studies using non-human primates (NHPs) were performed to induce immune tolerance after solid organ transplantation by conducting BMT simultaneously. However, dose optimization of CP and F...
1 Citations
#1Naoya Uchida (NIH: National Institutes of Health)H-Index: 19
#2Tina Nassehi (NIH: National Institutes of Health)H-Index: 6
Last. John F. Tisdale (NIH: National Institutes of Health)H-Index: 53
view all 13 authors...
Busulfan conditioning is utilized for hematopoietic stem cell (HSC) depletion in the context of HSC gene-therapy conditioning but may result in insufficient immunosuppression. In this study, we evaluated whether additional immunosuppression is required for efficient engraftment of gene-modified cells using a rhesus HSC lentiviral gene-therapy model. We transduced half of rhesus CD34+ cells with an enhanced green fluorescent protein (GFP)-encoding vector (immunogenic) and the other half with a γ-...
9 CitationsSource
#1Ismail M. Meraz (University of Texas MD Anderson Cancer Center)H-Index: 10
#2Mourad Majidi (University of Texas MD Anderson Cancer Center)H-Index: 9
Last. Jack A. Roth (University of Texas MD Anderson Cancer Center)H-Index: 127
view all 12 authors...
Human tumor xenograft models do not replicate the human immune system and tumor microenvironment. We developed an improved humanized mouse model, derived from fresh cord blood CD34+ stem cells (CD34+ HSCs), and combined it with lung cancer cell line-derived human xenografts or patient-derived xenografts (Hu-PDXs). Fresh CD34+ HSCs could reconstitute detectable mature human leukocytes (hCD45+) in mice at four weeks without the onset of graft-versus-host disease (GVHD). Repopulated human T cells, ...
30 CitationsSource
#1Mayra A. Carrillo (UCLA: University of California, Los Angeles)H-Index: 8
#2Anjie Zhen (UCLA: University of California, Los Angeles)H-Index: 12
Last. Scott G. Kitchen (UCLA: University of California, Los Angeles)H-Index: 29
view all 3 authors...
HIV and cancer remain prevailing sources of morbidity and mortality worldwide. There are current efforts to discover novel therapeutic strategies for the treatment or cure of these diseases. Humanized mouse models provide the investigative tool to study the interaction between HIV or cancer and the human immune system in vivo. These humanized models consist of immunodeficient mice transplanted with human cells, tissues, or hematopoietic stem cells that results in reconstitution with a nearly ful...
20 CitationsSource
#1Benjamin J. Burwitz (OHSU: Oregon Health & Science University)H-Index: 26
#2Helen L. Wu (OHSU: Oregon Health & Science University)H-Index: 10
Last. Jonah B. Sacha (OHSU: Oregon Health & Science University)H-Index: 29
view all 29 authors...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a critically important therapy for hematological malignancies, inborn errors of metabolism, and immunodeficiency disorders, yet complications such as graft-vs.-host disease (GvHD) limit survival. Development of anti-GvHD therapies that do not adversely affect susceptibility to infection or graft-vs.-tumor immunity are hampered by the lack of a physiologically relevant, preclinical model of allogeneic HSCT. Here we show a spectrum of di...
15 CitationsSource
Cited By1
Abstract null null Chimeric antigen receptor (CAR) T cells have largely been successful in treating hematological malignancies in the clinic but have not been as effective in treating solid tumors, in part, owing to poor access and the immunosuppressive tumor microenvironment. In addition, CAR-T therapy can cause potentially life-threatening side effects, including cytokine release syndrome and neurotoxicity. Current preclinical testing of CAR-T therapy efficacy is typically performed in mouse t...